Plasmodium falciparum ATP4 inhibitors to treat malaria: worthy successors to artemisinin?
Progress in controlling malaria has slowed in recent years and the annual death toll remains above 400 000 globally, with most deaths caused by Plasmodium falciparum.1 The joint threats of increasing resistance to insecticides, artemisinin derivatives, and almost all other antimalarials in current u...
Gespeichert in:
| Veröffentlicht in: | The Lancet infectious diseases 2020-08, Vol.20 (8), p.883-885 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 885 |
|---|---|
| container_issue | 8 |
| container_start_page | 883 |
| container_title | The Lancet infectious diseases |
| container_volume | 20 |
| creator | Ashley, Elizabeth A Phyo, Aung Pyae |
| description | Progress in controlling malaria has slowed in recent years and the annual death toll remains above 400 000 globally, with most deaths caused by Plasmodium falciparum.1 The joint threats of increasing resistance to insecticides, artemisinin derivatives, and almost all other antimalarials in current use make the development of new classes of antimalarials a high priority. Studies done over the past 10 years have identified the malaria parasite cation ATPase P falciparum ATP4 as a promising target for novel antimalarials by phenotypic screening.2 It plays a role in maintaining low intracellular sodium cation concentrations in P falciparum.3 Inhibition of P falciparum ATP4 disrupts sodium ion homeostasis and is lethal for the parasite. Artefenomel Artesunate before 2008* Artesunate after 2008 Cipargamin Ganaplacide SJ733 (600 mg dose) Drug class Synthetic trioxolane Artemisinin derivative Artemisinin derivative Plasmodium falciparum ATP4 inhibitor Imidazolopiperazine P falciparum ATP4 inhibitor Median parasite clearance half-life (h)† 3·6 3·2 5·3 0·9 3·5 3·6 Mean terminal elimination half-life (h) 62·3 (for 400 mg cohort) |
| doi_str_mv | 10.1016/S1473-3099(20)30139-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2388825794</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1473309920301390</els_id><sourcerecordid>2388825794</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-f7965b99cb25aa0932b323c2580aff60f15af4382ff7737f021d3424cb068dc13</originalsourceid><addsrcrecordid>eNqFkMtKxDAUhoMoXkYfQSm40UX15DZp3YiINxAU1IWrkKYJRtpmTFLFtzfOjC7cuMohfOc_Px9CuxiOMODp8QNmgpYU6vqAwCEFTOsSVtBm_mYlY1yszucFsoG2YnwFwAIDW0cblBDBK4E30fN9p2LvWzf2hVWddjMV8nj2eM8KN7y4xiUfYpF8kYJRqehVp4JTJ8WHD-nls4ij1ibGJaNCMr2LbnDD6TZay4HR7CzfCXq6vHg8vy5v765uzs9uS80YpNKKesqbutYN4UpBTUlDCdWEV6CsnYLFXFlGK2KtEFRYILiljDDdwLRqNaYTdLDInQX_NpqYZG6gTdepwfgxSkKrqiJc1Cyj-3_QVz-GIbeThJEqgzwXmCC-oHTwMQZj5Sy4XoVPiUF-u5dz9_JbrCQg5-4l5L29ZfrY9Kb93fqRnYHTBWCyjndngozamUGb1gWjk2y9--fEF2PXktI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2428388509</pqid></control><display><type>article</type><title>Plasmodium falciparum ATP4 inhibitors to treat malaria: worthy successors to artemisinin?</title><source>Elsevier ScienceDirect Journals</source><source>ProQuest Central UK/Ireland</source><creator>Ashley, Elizabeth A ; Phyo, Aung Pyae</creator><creatorcontrib>Ashley, Elizabeth A ; Phyo, Aung Pyae</creatorcontrib><description>Progress in controlling malaria has slowed in recent years and the annual death toll remains above 400 000 globally, with most deaths caused by Plasmodium falciparum.1 The joint threats of increasing resistance to insecticides, artemisinin derivatives, and almost all other antimalarials in current use make the development of new classes of antimalarials a high priority. Studies done over the past 10 years have identified the malaria parasite cation ATPase P falciparum ATP4 as a promising target for novel antimalarials by phenotypic screening.2 It plays a role in maintaining low intracellular sodium cation concentrations in P falciparum.3 Inhibition of P falciparum ATP4 disrupts sodium ion homeostasis and is lethal for the parasite. Artefenomel Artesunate before 2008* Artesunate after 2008 Cipargamin Ganaplacide SJ733 (600 mg dose) Drug class Synthetic trioxolane Artemisinin derivative Artemisinin derivative Plasmodium falciparum ATP4 inhibitor Imidazolopiperazine P falciparum ATP4 inhibitor Median parasite clearance half-life (h)† 3·6 3·2 5·3 0·9 3·5 3·6 Mean terminal elimination half-life (h) 62·3 (for 400 mg cohort) <1 <1 20·8 40·8 17·4 (median value) Adverse events Raised creatine phosphokinase concentrations Allergic reactions (<1 in 3000) Allergic reactions (<1 in 3000) Raised aminotransferase concentrations Raised aminotransferase concentrations Raised aminotransferase concentrations Resistance P falciparum kelch13 mutations P falciparum kelch13 mutations P falciparum kelch13 mutations P falciparum ATP4 mutations P falciparum carl mutations P falciparum ATP4 mutations Mean minimum inhibitory concentration (ng/mL) 4·1 2·2 2·2 0·1 58 122 Table Characteristics of SJ733 compared with other fast-acting antimalarial drugs</description><identifier>ISSN: 1473-3099</identifier><identifier>EISSN: 1474-4457</identifier><identifier>DOI: 10.1016/S1473-3099(20)30139-0</identifier><identifier>PMID: 32275871</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject>Adenosine triphosphatase ; Allergic reactions ; Artemisinin ; Artesunate ; Cations ; Creatine ; Creatine kinase ; Drug dosages ; Fatalities ; Half-life ; Homeostasis ; Hypersensitivity ; Infectious diseases ; Inhibitors ; Insecticide resistance ; Insecticides ; Malaria ; Minimum inhibitory concentration ; Mutation ; Parasites ; Pharmacokinetics ; Plasmodium falciparum ; Sodium ; Studies ; Vector-borne diseases</subject><ispartof>The Lancet infectious diseases, 2020-08, Vol.20 (8), p.883-885</ispartof><rights>2020 Elsevier Ltd</rights><rights>2020. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-f7965b99cb25aa0932b323c2580aff60f15af4382ff7737f021d3424cb068dc13</citedby><cites>FETCH-LOGICAL-c440t-f7965b99cb25aa0932b323c2580aff60f15af4382ff7737f021d3424cb068dc13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2428388509?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,64361,64363,64365,65309,72215</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32275871$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ashley, Elizabeth A</creatorcontrib><creatorcontrib>Phyo, Aung Pyae</creatorcontrib><title>Plasmodium falciparum ATP4 inhibitors to treat malaria: worthy successors to artemisinin?</title><title>The Lancet infectious diseases</title><addtitle>Lancet Infect Dis</addtitle><description>Progress in controlling malaria has slowed in recent years and the annual death toll remains above 400 000 globally, with most deaths caused by Plasmodium falciparum.1 The joint threats of increasing resistance to insecticides, artemisinin derivatives, and almost all other antimalarials in current use make the development of new classes of antimalarials a high priority. Studies done over the past 10 years have identified the malaria parasite cation ATPase P falciparum ATP4 as a promising target for novel antimalarials by phenotypic screening.2 It plays a role in maintaining low intracellular sodium cation concentrations in P falciparum.3 Inhibition of P falciparum ATP4 disrupts sodium ion homeostasis and is lethal for the parasite. Artefenomel Artesunate before 2008* Artesunate after 2008 Cipargamin Ganaplacide SJ733 (600 mg dose) Drug class Synthetic trioxolane Artemisinin derivative Artemisinin derivative Plasmodium falciparum ATP4 inhibitor Imidazolopiperazine P falciparum ATP4 inhibitor Median parasite clearance half-life (h)† 3·6 3·2 5·3 0·9 3·5 3·6 Mean terminal elimination half-life (h) 62·3 (for 400 mg cohort) <1 <1 20·8 40·8 17·4 (median value) Adverse events Raised creatine phosphokinase concentrations Allergic reactions (<1 in 3000) Allergic reactions (<1 in 3000) Raised aminotransferase concentrations Raised aminotransferase concentrations Raised aminotransferase concentrations Resistance P falciparum kelch13 mutations P falciparum kelch13 mutations P falciparum kelch13 mutations P falciparum ATP4 mutations P falciparum carl mutations P falciparum ATP4 mutations Mean minimum inhibitory concentration (ng/mL) 4·1 2·2 2·2 0·1 58 122 Table Characteristics of SJ733 compared with other fast-acting antimalarial drugs</description><subject>Adenosine triphosphatase</subject><subject>Allergic reactions</subject><subject>Artemisinin</subject><subject>Artesunate</subject><subject>Cations</subject><subject>Creatine</subject><subject>Creatine kinase</subject><subject>Drug dosages</subject><subject>Fatalities</subject><subject>Half-life</subject><subject>Homeostasis</subject><subject>Hypersensitivity</subject><subject>Infectious diseases</subject><subject>Inhibitors</subject><subject>Insecticide resistance</subject><subject>Insecticides</subject><subject>Malaria</subject><subject>Minimum inhibitory concentration</subject><subject>Mutation</subject><subject>Parasites</subject><subject>Pharmacokinetics</subject><subject>Plasmodium falciparum</subject><subject>Sodium</subject><subject>Studies</subject><subject>Vector-borne diseases</subject><issn>1473-3099</issn><issn>1474-4457</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkMtKxDAUhoMoXkYfQSm40UX15DZp3YiINxAU1IWrkKYJRtpmTFLFtzfOjC7cuMohfOc_Px9CuxiOMODp8QNmgpYU6vqAwCEFTOsSVtBm_mYlY1yszucFsoG2YnwFwAIDW0cblBDBK4E30fN9p2LvWzf2hVWddjMV8nj2eM8KN7y4xiUfYpF8kYJRqehVp4JTJ8WHD-nls4ij1ibGJaNCMr2LbnDD6TZay4HR7CzfCXq6vHg8vy5v765uzs9uS80YpNKKesqbutYN4UpBTUlDCdWEV6CsnYLFXFlGK2KtEFRYILiljDDdwLRqNaYTdLDInQX_NpqYZG6gTdepwfgxSkKrqiJc1Cyj-3_QVz-GIbeThJEqgzwXmCC-oHTwMQZj5Sy4XoVPiUF-u5dz9_JbrCQg5-4l5L29ZfrY9Kb93fqRnYHTBWCyjndngozamUGb1gWjk2y9--fEF2PXktI</recordid><startdate>20200801</startdate><enddate>20200801</enddate><creator>Ashley, Elizabeth A</creator><creator>Phyo, Aung Pyae</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20200801</creationdate><title>Plasmodium falciparum ATP4 inhibitors to treat malaria: worthy successors to artemisinin?</title><author>Ashley, Elizabeth A ; Phyo, Aung Pyae</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-f7965b99cb25aa0932b323c2580aff60f15af4382ff7737f021d3424cb068dc13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adenosine triphosphatase</topic><topic>Allergic reactions</topic><topic>Artemisinin</topic><topic>Artesunate</topic><topic>Cations</topic><topic>Creatine</topic><topic>Creatine kinase</topic><topic>Drug dosages</topic><topic>Fatalities</topic><topic>Half-life</topic><topic>Homeostasis</topic><topic>Hypersensitivity</topic><topic>Infectious diseases</topic><topic>Inhibitors</topic><topic>Insecticide resistance</topic><topic>Insecticides</topic><topic>Malaria</topic><topic>Minimum inhibitory concentration</topic><topic>Mutation</topic><topic>Parasites</topic><topic>Pharmacokinetics</topic><topic>Plasmodium falciparum</topic><topic>Sodium</topic><topic>Studies</topic><topic>Vector-borne diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ashley, Elizabeth A</creatorcontrib><creatorcontrib>Phyo, Aung Pyae</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ashley, Elizabeth A</au><au>Phyo, Aung Pyae</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasmodium falciparum ATP4 inhibitors to treat malaria: worthy successors to artemisinin?</atitle><jtitle>The Lancet infectious diseases</jtitle><addtitle>Lancet Infect Dis</addtitle><date>2020-08-01</date><risdate>2020</risdate><volume>20</volume><issue>8</issue><spage>883</spage><epage>885</epage><pages>883-885</pages><issn>1473-3099</issn><eissn>1474-4457</eissn><abstract>Progress in controlling malaria has slowed in recent years and the annual death toll remains above 400 000 globally, with most deaths caused by Plasmodium falciparum.1 The joint threats of increasing resistance to insecticides, artemisinin derivatives, and almost all other antimalarials in current use make the development of new classes of antimalarials a high priority. Studies done over the past 10 years have identified the malaria parasite cation ATPase P falciparum ATP4 as a promising target for novel antimalarials by phenotypic screening.2 It plays a role in maintaining low intracellular sodium cation concentrations in P falciparum.3 Inhibition of P falciparum ATP4 disrupts sodium ion homeostasis and is lethal for the parasite. Artefenomel Artesunate before 2008* Artesunate after 2008 Cipargamin Ganaplacide SJ733 (600 mg dose) Drug class Synthetic trioxolane Artemisinin derivative Artemisinin derivative Plasmodium falciparum ATP4 inhibitor Imidazolopiperazine P falciparum ATP4 inhibitor Median parasite clearance half-life (h)† 3·6 3·2 5·3 0·9 3·5 3·6 Mean terminal elimination half-life (h) 62·3 (for 400 mg cohort) <1 <1 20·8 40·8 17·4 (median value) Adverse events Raised creatine phosphokinase concentrations Allergic reactions (<1 in 3000) Allergic reactions (<1 in 3000) Raised aminotransferase concentrations Raised aminotransferase concentrations Raised aminotransferase concentrations Resistance P falciparum kelch13 mutations P falciparum kelch13 mutations P falciparum kelch13 mutations P falciparum ATP4 mutations P falciparum carl mutations P falciparum ATP4 mutations Mean minimum inhibitory concentration (ng/mL) 4·1 2·2 2·2 0·1 58 122 Table Characteristics of SJ733 compared with other fast-acting antimalarial drugs</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>32275871</pmid><doi>10.1016/S1473-3099(20)30139-0</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1473-3099 |
| ispartof | The Lancet infectious diseases, 2020-08, Vol.20 (8), p.883-885 |
| issn | 1473-3099 1474-4457 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2388825794 |
| source | Elsevier ScienceDirect Journals; ProQuest Central UK/Ireland |
| subjects | Adenosine triphosphatase Allergic reactions Artemisinin Artesunate Cations Creatine Creatine kinase Drug dosages Fatalities Half-life Homeostasis Hypersensitivity Infectious diseases Inhibitors Insecticide resistance Insecticides Malaria Minimum inhibitory concentration Mutation Parasites Pharmacokinetics Plasmodium falciparum Sodium Studies Vector-borne diseases |
| title | Plasmodium falciparum ATP4 inhibitors to treat malaria: worthy successors to artemisinin? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T14%3A06%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasmodium%20falciparum%20ATP4%20inhibitors%20to%20treat%20malaria:%20worthy%20successors%20to%20artemisinin?&rft.jtitle=The%20Lancet%20infectious%20diseases&rft.au=Ashley,%20Elizabeth%20A&rft.date=2020-08-01&rft.volume=20&rft.issue=8&rft.spage=883&rft.epage=885&rft.pages=883-885&rft.issn=1473-3099&rft.eissn=1474-4457&rft_id=info:doi/10.1016/S1473-3099(20)30139-0&rft_dat=%3Cproquest_cross%3E2388825794%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2428388509&rft_id=info:pmid/32275871&rft_els_id=S1473309920301390&rfr_iscdi=true |